| Literature DB >> 30984178 |
Marsha S Russell1, Marybeth Creskey1, Abenaya Muralidharan1,2, Changgui Li3, Jun Gao1, Wangxue Chen4, Louise Larocque1, Jessie R Lavoie1, Aaron Farnsworth1, Michael Rosu-Myles1,2, Anwar M Hashem5, Carole L Yauk6, Jingxin Cao7, Gary Van Domselaar7, Terry Cyr1, Xuguang Li1,2.
Abstract
Respiratory syncytial virus (RSV) infection is a severe threat to young children and the elderly. Despite decades of research, no vaccine has been approved. Notably, instead of affording protection, a formalin-inactivated RSV vaccine induced severe respiratory disease including deaths in vaccinated children in a 1960s clinical trial; however, recent studies indicate that other forms of experimental vaccines can also induce pulmonary pathology in pre-clinical studies. These findings suggest that multiple factors/pathways could be involved in the development of enhanced respiratory diseases. Clearly, a better understanding of the mechanisms underlying such adverse reactions is critically important for the development of safe and efficacious vaccines against RSV infection, given the exponential growth of RSV vaccine clinical trials in recent years. By employing an integrated systems biology approach in a pre-clinical cotton rat model, we unraveled a complex network of pulmonary canonical pathways leading to disease development in vaccinated animals upon subsequent RSV infections. Cytokines including IL-1, IL-6 GRO/IL-8, and IL-17 in conjunction with mobilized pulmonary inflammatory cells could play important roles in disease development, which involved a wide range of host responses including exacerbated pulmonary inflammation, oxidative stress, hyperreactivity, and homeostatic imbalance between coagulation and fibrinolysis. Moreover, the observed elevated levels of MyD88 implicate the involvement of this critical signal transduction module as the central node of the inflammatory pathways leading to exacerbated pulmonary pathology. Finally, the immunopathological consequences of inactivated vaccine immunization and subsequent RSV exposure were further substantiated by histological analyses of these key proteins along with inflammatory cytokines, while hypercoagulation was supported by increased pulmonary fibrinogen/fibrin accompanied by reduced levels of plasma D-dimers. Enhanced respiratory disease associated with inactivated RSV vaccine involves a complex network of host responses, resulting in significant pulmonary lesions and clinical manifestations such as tachypnea and airway obstruction. The mechanistic insight into the convergence of different signal pathways and identification of biomarkers could help facilitate the development of safe and effective RSV vaccine and formulation of new targeted interventions.Entities:
Keywords: RSV vaccine-enhanced disease; RSV vaccines; cytokine; hypercoagulation; mechanistic studies; proteomics; systems biology
Year: 2019 PMID: 30984178 PMCID: PMC6449435 DOI: 10.3389/fimmu.2019.00597
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Development of VERD following RSV challenge of FI-RSV-immunized cotton rats. Vaccinated cotton rats were monitored daily for 5 days after RSV challenge for airway obstruction using a whole body plethysmograph (n = 6). Results are displayed as fold change from 0 h when challenged with RSV (day 49 of study) for (A) breaths per minute (bpm) and (B) Penh (120 h after viral challenge). Significant differences between time = 0 h post-challenge for each group and 72, 96, and 120 h of the respective group was assessed using one-way ANOVA, *p < 0.05, **p < 0.01. (C) Representative pictures of H&E-stained lung tissue obtained from animals in the indicated groups 5 days after challenge with RSV (40× magnification). (D) Lung pathology scores (bronchiolitis and alveolitis) of animals in the indicated groups 5 days after challenge with RSV. (n = 6) (E) Lung viral titres measured in animals in the indicated groups 5 days after challenge with RSV. Data are represented as mean ± SEM from two independent experiments (n = 6). Significant differences between FI-RSV vaccinated group and the other groups were assessed using one-way ANOVA, *p < 0.05, **p < 0.01.
Figure 2Poor neutralizing antibody profile of cotton rats vaccinated with FI-RSV exhibiting VERD following RSV challenge despite similar levels of IgG. (A) Neutralizing antibody response in serum of cotton rats vaccinated with FI-RSV, pre-exposed to RSV or mock vaccinated and challenged with RSV 5 days post-challenge (n = 10). (B) ELISA quantification of IgG against RSV in the serum of cotton rats 5 days post-challenge in animals that were immunized with FI-RSV or pre-exposed to RSV (n = 10).
Figure 3(A) Heat map of the comparative analysis of the canonical pathways significantly enriched in the indicated groups relative to PBS controls. (B) Heat map of the comparative analysis of the statistically significant upstream regulators predicted to be involved in the indicated groups. For both heat maps, only those with a Z-score equal to ± 2 are displayed. (n = 12).
Pathways and proteins associated with lung cellular infiltrates in FI-RSV.
| Neutrophil | Cell movement of neutrophils | 2.85 | ALB(1.341) |
| Adhesion of neutrophils | 2.40 | ANGPT2(1.34) | |
| Activation of neutrophils | 1.76 | AHR(−1.22) | |
| Binding of neutrophils | 1.73 | C3(1.419) | |
| Chemotaxis of neutrophils | 1.64 | ALOX5(1.277) | |
| IL-8 signaling | 2.89 | AKT1(1.21) | |
| fMLP signaling in neutrophils | 2 | GNB2(−1.3) | |
| IL-17A signaling in airway cells | 2 | AKT1(1.21) | |
| Macrophage | Activation of macrophages | 2.09 | ABHD12(1.487) |
| Chemotaxis of macrophages | 2 | CHUK(1.427) | |
| Recruitment of macrophages | 1.82 | ANGPT2(1.34) | |
| Fcy receptor-mediated phagocytosis in macrophages | 2 | AKT1(1.21) | |
| Lymphocyte | Quantity of B lymphocytes | 2.16 | AHR(−1.22) |
| IL-6 signaling | 2.24 | AKT1(1.21) | |
| IL-1 Signaling | 2.45 | CHUK(1.427) | |
| IL-17A Signaling in airway cells | 2 | AKT1(1.21) | |
| B cell receptor signaling | 2.33 | AKT1(1.21) | |
| Eosinophil | no specific pathway | N/A | Epx(1.4) |
IPA canonical pathways or functional annotations associated with cellular infiltrates observed in the lungs of FI-RSV infected animals. The z-score cut-off was lowered to >1.5 and < -1.5 to reveal those pathways or functional annotations that were not significant yet informative in understating the overall cellular infiltration. Those with z-score >2 and < -2 were considered significant.
Figure 4Validation of key proteins in the proteomics datasets. Immunohistochemical detection of MYD88 (A) and ITGAM (B) in lungs. For each section 15 fields of view were counted for positively stained cells in the alveoli (40× magnification). Black arrows indicate the positive staining by diaminobenzidine (DAB) substrate. The percentages of total area stained as well as the percentages of positive cells for each cytokine were calculated using one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001 (n = 6). Gene expression of NFKB2 (C) in the lungs was normalized to β-actin and fold change was expressed over the PBS group using the ΔΔCt method. Statistical differences in fold change were calculated using one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (n = 6).
Figure 5Higher expression levels of IL-1 and IL-6 cytokines and chemoattractant GRO in FI-RSV vaccinated cotton rats. Detection of pulmonary interleukin-1 (A) and interleukin-6 (B) was conducted using immunohistochemistry. For each section 15 fields of view were counted for positively stained cells in the alveoli (40× magnification). Black arrows indicate the positive staining by diaminobenzidine (DAB) substrate. The percentages of total area stained as well as the percentages of positive cells for each cytokine were calculated using one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001 (n = 6). Gene expression of GRO (C) in the lungs was normalized to β-actin and fold change was expressed over the PBS group using the ΔΔCt method. Statistical differences in fold change were calculated using one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (n = 6).
Figure 6Predicted disease and functional outcomes from Ingenuity Pathway Analysis highlights the possibility of a hypercoagulation state. IPA downstream analysis results are displayed with the p-value of overlap (A) showing the likelihood that the disease and/or functional outcome occur. Those that gave a –log1.3 were considered significant (yellow line). Only the first 14 most highly predicted outcomes are displayed. (B) Heat map of the z-score (>2 or <-2) showing the degree of up-regulation or down regulation of the respective disease or functional annotations in each of the groups (n = 12).
Figure 7FI-RSV vaccinated cotton rats demonstrate increased expression of fibrinogen alpha-chain and the presence of fibrin deposits 5 days after RSV challenge. (A) Immunohistochemical detection of fibrinogen alpha-chain in the lung. Pictures show a representative staining of each vaccine group at 40× objective. The percentage of total area stained was calculated using one-way ANOVA, **p < 0.01, (n = 6). (B) MSB staining for fibrin. Pictures show a representative area of lung containing positive stain for fibrin (arrowhead). In the FI-RSV group, alveolitis with a mixture of macrophages and neutrophils in alveolar spaces (full arrows) was observed. Additionally, there is bronchiolitis with mainly macrophages and some neutrophils and small amounts of red staining (MSB stain) fibrin (arrowhead) in the lumen in this vaccine group. Inset scale = 120 μm, large picture scale = 50 μm.
Figure 8FI-RSV vaccinated cotton rats show low plasma D-dimer levels 5 days after RSV challenge. Plasma D-dimer levels were measure with ELISA. Significant differences between FI-RSV and the other vaccine groups were calculated using one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001 (n = 10).